Document is current
Any future updates will be listed below
-
Authors
Shiozawa, Manabu
Sunakawa, Yu https://orcid.org/0000-0002-0163-7543
Watanabe, Takanori
Ota, Hirofumi
Yasui, Hisateru
Yabuno, Taichi
Tei, Mitsuyoshi
Kochi, Mitsugu
Manaka, Dai
Ohori, Hisatsugu
Yamaguchi, Tatsuro https://orcid.org/0000-0001-8454-1995
Sagawa, Tamotsu
Kotaka, Masahito
Kubota, Yutaro
Sekikawa, Takashi
Nakamura, Masato
Takeuchi, Masahiro
Ichikawa, Wataru
Fujii, Masashi
Tsuji, Akihito
-
Funding
Funding for this research was provided by:
Merck KGaA
- License Information
-
More Information
Article History
Received: 6 March 2024
Accepted: 13 November 2024
First Online: 25 November 2024
Competing interests
: M.S. has received honoraria from Chugai Pharmaceutical Co., Ltd, Eli Lilly Japan K.K., Takeda Co., Ltd, Taiho Pharmaceutical Co., Ltd, Merck Biopharma Co., Ltd, Ono Pharmaceutical Co., Ltd, Johnson & Johnson K.K, Kaken Pharmaceutical Co., Ltd. Y.S. has received honoraria from Eli Lilly Japan K.K., Bristol-Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ono Pharmaceutical Co., Ltd., Merck Biopharma Co., Ltd., Taiho Pharmaceutical Co., Ltd., Bayer Yakuhin, Ltd., Daiichi Sankyo Co., Ltd., MSD K.K., Novartis Pharmaceuticals, Astellas Pharma Inc., Sysmex, and Guardant Health, and has also received grants from Chugai Pharmaceutical Co., Ltd. and Taiho Pharmaceutical Co., Ltd. T.Y. has received honoraria from Chugai Pharmaceutical Co., Ltd, Taiho Pharmaceutical Co., Ltd, FALCO Biosystems Ltd, Asahi Kasei Pharma Corporation Co., Ltd, Eli Lilly Japan K.K., Ono Pharmaceutical Co., Ltd. M.K. has received honoraria from Chugai Pharmaceutical Co., Ltd, Eli Lilly Japan K.K., Takeda Co., Ltd, Taiho Pharmaceutical Co., Ltd, Yakult Honsha Co., Ltd. M.N. has received honoraria from Bayer Co., Ltd, Chugai Pharmaceutical Co., Ltd, Daiichi Sankyo Co., Ltd, Eli Lilly Japan K.K., Merck Bio Pharma Co., Ltd, MSD K.K., Nihon Servier Co., Ltd, Ono Pharmaceutical Co., Ltd, Taiho Pharmaceutical Co., Ltd, Takeda Co., Ltd, and Yakult Honsha Co., Ltd. W.I. has received honoraria from Taiho Pharmaceutical Co., Ltd, Chugai Pharmaceutical Co., Ltd, Daiichi Sankyo Co., Ltd, Takeda Pharmaceutical Co., Ltd, Ono Pharmaceutical Co., Ltd, Merck Biopharma Co., Ltd, Yakult Honsha Co., Ltd, Bristol-Myers Squibb K.K., AstraZeneca K.K., Kyowa Kirin Co., Ltd, MSD K.K,., Nippon Kayaku Co., Ltd, and grants from Taiho Pharmaceutical Co., Ltd, Chugai Pharmaceutical Co., Ltd, Daiichi Sankyo Co., Ltd, Shionogi & Co., Ltd, Takeda Pharmaceutical Co., Ltd, Ono Pharmaceutical Co., Ltd, and Merck. A.T. has received honoraria from Taiho Pharmaceutical Co., Ltd, Chugai Pharmaceutical Co., Ltd, Eli Lilly Japan K.K., Merck Serono Co., Ltd, Sanofi K.K., Bristol-Myers Squibb K.K. All other authors declare no competing interests.
